Appearance of Oral Erosive Lichen Planus during Interferon Alfa‐2a Therapy for Chronic Active Hepatitis C

Núñez, María; Miralles, Enrique S.; Liñero, Elena de las Heras; Ledo, A.

doi:10.1111/j.1346-8138.1995.tb03424.x

Cited by 11 publications

(5 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A monotherapy with interferon alpha (IFN-α) or combined therapy with IFN-α and ribavirin are standard treatments for chronic HCV infection. Different studies reported variable effects of IFN-α therapies on HCV-related OLP, i.e.., IFN-α either improved [63,64], aggravated [65,66], or triggered OLP lesions [67][68][69]. In Taiwanese patients with HCV, IFN-α and ribavirin combination therapy was associated with an increase in a sustained virologic response (SVR) rate of up to 60%.…”

Section: Therapeutic Management Of Oral Lichen Planus In Patients Witmentioning

confidence: 99%

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Meşter

Lucaciu

Ciobanu

et al. 2018

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

Oral lichen planus (OLP) is a chronic inflammatory disease characterized by the occurrence of multiple, symmetrical lesions in the oral cavity. Hepatitis C virus (HCV) infection has been suggested as an etiological factor in OLP. The purpose of this review was to summarize the current literature regarding the treatment of OLP in patients with HCV infection. An electronic search of the PubMed database was conducted until January 2018, using the following keywords: OLP, HCV, corticosteroids, retinoids, immunomodulatory agents, surgical interventions, photochemotherapy, laser therapy, interferon, ribavirin, and direct-acting antivirals. We selected the articles focusing on the clinical features and treatment management of OLP in patients with/without HCV infection. Topical corticosteroids are considered the first-line treatment in OLP. Calcineurin inhibitors or retinoids can be beneficial for recalcitrant OLP lesions. Systemic therapy should be used in the case of extensive and refractory lesions that involve extraoral sites. Surgical intervention is recommended for isolated lesions. In patients with HCV, monotherapy with interferon (IFN)-α may either improve, aggravate or trigger OLP lesions, while combined IFN-α and ribavirin therapy does not significantly influence the progression of lesions. Direct-acting antiviral (DAA) therapy appears to be a promising approach in patients with HCV-related OLP, as it can improve symptoms of both liver disease and OLP, with fewer side effects. Nevertheless, for clinical utility of DAAs in OLP patients, further studies with larger sample sizes, adequate treatment duration, and long term follow-up are required.

show abstract

Section: Therapeutic Management Of Oral Lichen Planus In Patients Witmentioning

confidence: 99%

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Meşter

Lucaciu

Ciobanu

et al. 2018

Bosn J of Basic Med Sci

View full text Add to dashboard Cite

show abstract

“…There has been 1 prior report describing the onset of OLL with IFN and ribavirin therapy in HCV-monoinfected subjects. [7][8][9][10][11][12][13][14][15][16][17][18] Considering these case reports (Table 1), it is important to note that the diagnostic criteria followed by the authors for discriminating OLP from OLL (and from OLDR in particular) are not always clearly stated because some of them arise after anti-HCV therapy. It is advisable, as we already stated, that clear diagnostic criteria be followed to diagnose OLP or OLL; the article of Van der Meij and van der Waal 3 is worth considering.…”

Section: Discussionmentioning

confidence: 99%

“…[4][5][6] Some researchers describe the onset and/or the worsening of OLL/OLP after the administration of anti-hepatitis C virus (HCV) therapy. [7][8][9][10][11][12][13][14][15][16][17][18] We describe the development of symptomatic OLLs, after the administration of anti-HCV therapy, in 2 human immunodeficiency virus (HIV)-HCVcoinfected subjects.…”

Section: Introductionmentioning

confidence: 99%

Oral Lichenoid Lesions in HIV-HCV-Coinfected Subjects During Antiviral Therapy: 2 Cases and Review of the Literature

Giuliani¹,

Lajolo²,

Sartorio³

et al. 2008

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Some dental materials and certain drugs may induce epithelial alterations, which clinically resemble oral lichen planus (OLP), on oral mucosa. But these alterations do not have all the clinical and/or the histological features of OLP; these lesions are known as oral lichenoid lesions (OLLs). Some researchers describe the onset and/or the worsening of OLL/OLP after the administration of anti-hepatitis C virus (HCV) therapy. In this article, we describe the development of symptomatic OLLs, as a consequence of anti-HCV therapy (interferon-alpha and ribavirine), in 2 human immunodeficiency virus-HCV-coinfected subjects. An immunological cause related to coinfection and administration of different medications could be responsible for the onset of OLLs. These new cases, together with the previous reports of a possible association between OLP and/or OLL and anti-HCV therapy, highlight the absolute need to monitor carefully the human immunodeficiency virus-HCV-coinfected subjects who are about to start the anti-HCV therapy and to define better the clinical and histopathological criteria to distinguish OLP from OLL.

show abstract

“…In a previous study, we showed the histopathological disappearance of OLP when HCV was eliminated by IFN therapy (64). On the other hand, IFN therapy may trigger the onset of OLP (65)(66)(67) or sometimes act as an aggravating factor (66,68,69). Recent studies have demonstrated improvements in OLP after the elimination of HCV via DAA treatment (70)(71)(72)(73)(74)(75).…”

Section: Oral Lichen Planus and Hepatitis C Virusmentioning

confidence: 94%

The role of dentists in controlling hepatocellular carcinoma in Japan (Review)

Nagao

2020

Exp Ther Med

View full text Add to dashboard Cite

In Japan, the method of treatment for hepatitis is well established due to the high rates of hepatitis C. However, the identification of patients with hepatitis who do not receive appropriate treatment poses a major problem. Some patients with this disease may need to consult with a dentist due to the development of extrahepatic manifestations, such as lichen planus, in the oral cavity. Alternatively, the dentist might discover patients with untreated hepatitis C and hepatitis B during routine dental examination. In such cases, the patient should be referred to a hepatologist for further examinations and treatment. Thus, dentists are required to act as 'gatekeepers of hepatitis'. Furthermore, Japanese dentists need to increase hepatitis B vaccine coverage for infection control. By acting as a 'care coordinator of hepatitis', the dentist will be able to contribute to the eradication of liver cancer in Japan, thereby eliminating the discrimination and prejudice against patients with hepatitis. Dentists need to have a deep understanding of liver disease from the viewpoints of both nosocomial infection control and treatment of oral diseases.

show abstract

Appearance of Oral Erosive Lichen Planus during Interferon Alfa‐2a Therapy for Chronic Active Hepatitis C

Cited by 11 publications

References 9 publications

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Clinical features and management of oral lichen planus (OLP) with emphasis on the management of hepatitis C virus (HCV)-related OLP

Oral Lichenoid Lesions in HIV-HCV-Coinfected Subjects During Antiviral Therapy: 2 Cases and Review of the Literature

The role of dentists in controlling hepatocellular carcinoma in Japan (Review)

Contact Info

Product

Resources

About